BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martínez Bedoya D, Dutoit V, Migliorini D. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. Front Immunol 2021;12:640082. [PMID: 33746981 DOI: 10.3389/fimmu.2021.640082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Abraham E, Trainor N, Ostrout N, Hewitt MM. Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt. Current Opinion in Biomedical Engineering 2021;20:100340. [DOI: 10.1016/j.cobme.2021.100340] [Reference Citation Analysis]
2 Haydar D, Ibañez-Vega J, Krenciute G. T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges. Front Oncol 2021;11:718030. [PMID: 34760690 DOI: 10.3389/fonc.2021.718030] [Reference Citation Analysis]
3 Wagner PM, Prucca CG, Caputto BL, Guido ME. Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy. Int J Mol Sci 2021;22:8289. [PMID: 34361055 DOI: 10.3390/ijms22158289] [Reference Citation Analysis]
4 Hussain A. Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00238-8] [Reference Citation Analysis]
5 Mansouri V, Yazdanpanah N, Rezaei N. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. Int Rev Immunol 2021;:1-20. [PMID: 34607523 DOI: 10.1080/08830185.2021.1984449] [Reference Citation Analysis]
6 Billmeier A, Khinvasara K, Lang F, Mohr J, Reidenbach D, Schork M, Yildiz I, Diken M. CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy. Hum Vaccin Immunother 2022;:1-10. [PMID: 35130105 DOI: 10.1080/21645515.2021.2024416] [Reference Citation Analysis]
7 Akbari P, Katsarou A, Daghighian R, van Mil LW, Huijbers EJ, Griffioen AW, van Beijnum JR. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022. [DOI: 10.1016/j.bbcan.2022.188701] [Reference Citation Analysis]
8 Damerval M, Fagnoni-Legat C, Louvrier A, Fischer S, Limat S, Clairet AL, Nerich V, Madelaine I, Kroemer M. ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature. Front Med (Lausanne) 2021;8:713047. [PMID: 34926483 DOI: 10.3389/fmed.2021.713047] [Reference Citation Analysis]
9 Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in Universal CAR-T Cell Therapy. Front Immunol 2021;12:744823. [PMID: 34691052 DOI: 10.3389/fimmu.2021.744823] [Reference Citation Analysis]
10 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward. Front Immunol 2021;12:765097. [PMID: 34777381 DOI: 10.3389/fimmu.2021.765097] [Reference Citation Analysis]